XGN
Bearish signalScored 2026-10-21 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Exagen Inc.
- Nom
- Exagen Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $176.8M
- Employés
- 216
- PDG
- John Aballi
- Site web
- https://www.exagen.com
- Marché
- ACRSBIOALFCRMDXHNEOSGHT
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 34 294 titres (~269 790,90 $ US)
- Insiders
- ABALLI JOHN
- Total bought
-
—
Avg buy (VWAP, 90d window) $7.46 vs last close $7.47 (+0.1%)
- Total sold
-
$418,572
Avg sell (VWAP, 90d window) $7.62 vs last close $7.47 (-2.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-10-16
- Liquidity
- Thin $2,735,865/day · 20d vol
- Last synced
-
2026-10-26 21:11:09
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-19 | Chernett Jorey | Buy · P | 14,000 | $7.46 | $104,440 | Form 4 |
| 2026-10-16 | ABALLI JOHN | Sell · S | 34,294 | $7.87 | $269,791 | Form 4 |
| 2026-09-01 | Black Jeffrey G. | Sell · S | 20,614 | $7.22 | $148,782 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-21 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
XGN combines deeply negative fundamentals (persistent losses, negative EBIT/EBITDA, inability to service debt) with a very weak catalyst score of 15, driven by meaningful insider selling from the CEO with zero…
The first sentence of the analysis written for XGN on 2026-10-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 3.45 · operating margin -21% — readings disagree
Suggested stop 4.21, nearest stored support minus 0.5 ATR(43.6% under the last close). Reward/risk to the next stored resistance is 0.38. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-20 Exagen (NASDAQ:XGN) CEO John Aballi Sells 34,294 Shares of Stock Exagen Inc. (NASDAQ: XGN - Get Free Report) CEO John Aballi sold 34,294 shares of the company''s stock in a transaction on Friday, October 16th. The stock was sold at an average price of $7.87, for a total value of $269,893.78. Following the transaction, the chief executive officer owned 805,540 shares in the company, valued at
- 2026-09-28 Universal Health Services (NYSE:UHS) versus Exagen (NASDAQ:XGN) Financial Analysis Universal Health Services (NYSE: UHS - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends. Institutional and Insider Ownership 86.0% of Universal Health
- 2026-09-21 Exagen Inc. (NASDAQ:XGN) Receives Consensus Recommendation of “Moderate Buy” from Analysts Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the
- 2026-09-16 InfuSystem (NYSE:INFU) & Exagen (NASDAQ:XGN) Head to Head Contrast Exagen (NASDAQ: XGN - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability. Earnings and Valuation This table compares Exagen and InfuSystem"s
- 2026-09-16 Exagen (NASDAQ:XGN) versus Gaxos.ai (NASDAQ:GXAI) Financial Review Exagen (NASDAQ: XGN - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Valuation and Earnings This table compares Exagen and Gaxos.ai"s
- 2026-08-27 Exagen Inc. (NASDAQ:XGN) Given Average Rating of “Moderate Buy” by Brokerages Shares of Exagen Inc. (NASDAQ: XGN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation
- 2026-08-24 Reviewing Amplifon (OTCMKTS:AMFPF) & Exagen (NASDAQ:XGN) Amplifon (OTCMKTS:AMFPF - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation. Analyst Ratings This is a breakdown of current ratings and
- 2026-08-04 Exagen Q2 Earnings Call Highlights Exagen NASDAQ: XGN reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to adjusted EBITDA break-even.
- 2026-08-04 Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript
- 2026-08-04 Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates Exagen Inc. (XGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 58.3% | 59.5% | 56.1% | 46.9% | 57.4% | |
| Ebit Margin | -23.4% | -23.1% | -40.6% | -99.2% | -49.8% | |
| Ebitda Margin | -20.2% | -20.0% | -36.4% | -95.8% | -47.8% | |
| Operating Profit Margin | -21.1% | -24.5% | -43.5% | -101.1% | -49.8% | |
| Pretax Profit Margin | -29.9% | -27.1% | -45.0% | -104.6% | -55.2% | |
| Continuous Operations Profit Margin | -30.0% | -27.2% | -45.1% | -104.0% | -55.6% | |
| Net Profit Margin | -30.0% | -27.2% | -45.1% | -104.0% | -55.6% | |
| Bottom Line Profit Margin | -30.0% | -27.2% | -45.1% | -104.0% | -55.6% | |
| Current Ratio | 3.453 | 2.699 | 4.020 | 7.546 | 12.099 | |
| Quick Ratio | 3.453 | 2.699 | 4.020 | 7.546 | 12.099 | |
| Solvency Ratio | -0.440 | -0.381 | -0.628 | -1.047 | -0.673 | |
| Cash Ratio | 2.276 | 1.632 | 3.066 | 6.484 | 10.672 | |
| Price To Earnings Ratio | -6.538 | -4.940 | -1.485 | -0.866 | -6.923 | |
| Price To Earnings Growth Ratio | -0.543 | 0.130 | 0.029 | -0.013 | -0.254 | |
| Forward Price To Earnings Growth Ratio | -0.543 | 0.130 | 0.029 | -0.013 | -0.254 | |
| Price To Earnings Diluted Ratio | -6.538 | -4.940 | -1.485 | -0.866 | -6.923 | |
| Price To Earnings Diluted Growth Ratio | -0.543 | 0.130 | 0.029 | -0.013 | -0.254 | |
| Price To Book Ratio | 7.512 | 7.823 | 1.550 | 0.966 | 2.187 | |
| Price To Sales Ratio | 1.969 | 1.341 | 0.670 | 0.900 | 3.846 | |
| Price To Free Cash Flow Ratio | -9.188 | -5.411 | -2.301 | -1.124 | -8.205 | |
| Price To Operating Cash Flow Ratio | -9.620 | -5.620 | -2.433 | -1.275 | -9.165 | |
| Debt To Assets Ratio | 0.443 | 0.519 | 0.408 | 0.408 | 0.227 | |
| Debt To Equity Ratio | 1.473 | 2.432 | 1.024 | 0.829 | 0.330 | |
| Debt To Capital Ratio | 0.596 | 0.709 | 0.506 | 0.453 | 0.248 | |
| Long Term Debt To Capital Ratio | 0.561 | 0.675 | 0.459 | 0.404 | 0.244 | |
| Financial Leverage Ratio | 3.325 | 4.684 | 2.509 | 2.031 | 1.453 | |
| Working Capital Turnover Ratio | 2.308 | 1.890 | 1.062 | 0.548 | 0.585 | |
| Operating Cash Flow Ratio | -0.962 | -0.983 | -1.215 | -3.340 | -2.175 | |
| Operating Cash Flow Sales Ratio | -0.205 | -0.239 | -0.275 | -0.705 | -0.420 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.047 | 1.039 | 1.057 | 1.134 | 1.117 | |
| Debt Service Coverage Ratio | -2.724 | -4.199 | -7.382 | -16.445 | -7.247 | |
| Interest Coverage Ratio | -3.258 | -6.104 | -9.780 | -18.812 | -9.168 | |
| Short Term Operating Cash Flow Coverage Ratio | -21.190 | -31.392 | -54.780 | -169.179 | -34.530 | |
| Operating Cash Flow Coverage Ratio | -0.530 | -0.572 | -0.623 | -0.913 | -0.722 | |
| Capital Expenditure Coverage Ratio | -21.256 | -25.784 | -17.466 | -7.444 | -8.552 | |
| Dividend Paid And Capex Coverage Ratio | -21.256 | -25.784 | -17.466 | -7.444 | -8.552 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -9.251 | -6.801 | -1.144 | -0.316 | -4.951 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 58.3% | ▼-1.2% | ▲2.7% |
| Ebit Margin | -23.4% | ▼-0.3% | ▲23.8% |
| Ebitda Margin | -20.2% | ▼-0.2% | ▲23.8% |
| Operating Profit Margin | -21.1% | ▲3.4% | ▲26.9% |
| Pretax Profit Margin | -29.9% | ▼-2.8% | ▲22.5% |
| Continuous Operations Profit Margin | -30.0% | ▼-2.8% | ▲22.4% |
| Net Profit Margin | -30.0% | ▼-2.8% | ▲22.4% |
| Bottom Line Profit Margin | -30.0% | ▼-2.8% | ▲22.4% |
| Current Ratio | 3.453 | ▲0.754 | ▼-2.510 |
| Quick Ratio | 3.453 | ▲0.754 | ▼-2.510 |
| Solvency Ratio | -0.440 | ▼-0.059 | ▲0.194 |
| Cash Ratio | 2.276 | ▲0.644 | ▼-2.550 |
| Price To Earnings Ratio | -6.538 | ▼-1.598 | ▼-2.387 |
| Price To Earnings Growth Ratio | -0.543 | ▼-0.672 | ▼-0.412 |
| Forward Price To Earnings Growth Ratio | -0.543 | ▼-0.672 | ▼-0.412 |
| Price To Earnings Diluted Ratio | -6.538 | ▼-1.598 | ▼-2.387 |
| Price To Earnings Diluted Growth Ratio | -0.543 | ▼-0.672 | ▼-0.412 |
| Price To Book Ratio | 7.512 | ▼-0.311 | ▲3.504 |
| Price To Sales Ratio | 1.969 | ▲0.627 | ▲0.224 |
| Price To Free Cash Flow Ratio | -9.188 | ▼-3.777 | ▼-3.942 |
| Price To Operating Cash Flow Ratio | -9.620 | ▼-4.000 | ▼-3.998 |
| Debt To Assets Ratio | 0.443 | ▼-0.076 | ▲0.042 |
| Debt To Equity Ratio | 1.473 | ▼-0.959 | ▲0.255 |
| Debt To Capital Ratio | 0.596 | ▼-0.113 | ▲0.093 |
| Long Term Debt To Capital Ratio | 0.561 | ▼-0.115 | ▲0.092 |
| Financial Leverage Ratio | 3.325 | ▼-1.359 | ▲0.525 |
| Working Capital Turnover Ratio | 2.308 | ▲0.419 | ▲1.030 |
| Operating Cash Flow Ratio | -0.962 | ▲0.021 | ▲0.773 |
| Operating Cash Flow Sales Ratio | -0.205 | ▲0.034 | ▲0.164 |
| Free Cash Flow Operating Cash Flow Ratio | 1.047 | ▲0.008 | ▼-0.032 |
| Debt Service Coverage Ratio | -2.724 | ▲1.475 | ▲4.875 |
| Interest Coverage Ratio | -3.259 | ▲2.845 | ▲6.166 |
| Short Term Operating Cash Flow Coverage Ratio | -21.190 | ▲10.203 | ▲41.025 |
| Operating Cash Flow Coverage Ratio | -0.530 | ▲0.042 | ▲0.142 |
| Capital Expenditure Coverage Ratio | -21.256 | ▲4.529 | ▼-5.155 |
| Dividend Paid And Capex Coverage Ratio | -21.256 | ▲4.529 | ▼-5.155 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -9.251 | ▼-2.450 | ▼-4.758 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $131.1M | $74.6M | $35.2M | $41.0M | $185.8M | |
| Enterprise value | $124.6M | $75.8M | $21.9M | $13.8M | $114.4M | |
| EV / Sales | 1.87x | 1.36x | 0.42x | 0.30x | 2.37x | |
| EV / Op. cash flow | -9.14x | -5.71x | -1.52x | -0.43x | -5.64x | |
| EV / Free cash flow | -8.73x | -5.50x | -1.43x | -0.38x | -5.05x | |
| EV / EBITDA | -9.25x | -6.80x | -1.14x | -0.32x | -4.95x | |
| Net debt / EBITDA | 0.48x | -0.10x | 0.69x | 0.62x | 3.09x | |
| Current ratio | 3.45x | 2.70x | 4.02x | 7.55x | 12.10x | |
| Income quality | 0.68x | 0.88x | 0.61x | 0.68x | 0.76x | |
| Graham net-net | -$0 | -$0 | $0 | $1 | $4 | |
| Tax burden | 100.3% | 100.1% | 100.1% | 99.4% | 100.7% | |
| Interest burden | 127.7% | 117.4% | 111.0% | 105.4% | 110.9% | |
| Working capital | $34.7M | $22.9M | $35.9M | $63.0M | $103.4M | |
| Invested capital | $43.1M | $30.6M | $44.4M | $76.1M | $113.7M | |
| Return on assets | -34.4% | -33.8% | -41.6% | -55.0% | -21.8% | |
| Operating ROA | -27.4% | -26.8% | -31.9% | -43.9% | -23.8% | |
| Return on tangible assets | -34.4% | -33.8% | -41.6% | -55.0% | -22.8% | |
| Return on equity | -114.3% | -158.4% | -104.4% | -111.6% | -31.6% | |
| Return on invested capital | -30.0% | -41.4% | -49.3% | -58.3% | -21.0% | |
| Return on capital employed | -32.1% | -43.7% | -50.7% | -60.1% | -21.1% | |
| Earnings yield | -15.2% | -20.3% | -67.3% | -115.6% | -14.5% | |
| Free cash flow yield | -10.9% | -18.5% | -43.5% | -88.9% | -12.2% | |
| Capex / Op. cash flow | -4.7% | -3.9% | -5.7% | -13.4% | -11.7% | |
| Capex / Depreciation | 30.3% | 29.9% | 38.2% | 277.3% | 250.0% | |
| Capex / Sales | 1.0% | 0.9% | 1.6% | 9.5% | 4.9% | |
| SG&A / Sales | 70.0% | 74.4% | 90.3% | 114.2% | 92.2% | |
| R&D / Sales | 9.4% | 9.7% | 9.3% | 21.7% | 15.0% | |
| Stock comp / Sales | 3.2% | 3.2% | 6.9% | 10.3% | 9.8% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 4.5% | |
| Days sales outstanding | 60d | 51d | 46d | 49d | 73d | |
| Days payables outstanding | 55d | 67d | 49d | 46d | 44d | |
| Operating cycle | 60d | 51d | 46d | 49d | 73d | |
| Cash conversion cycle | 5d | -16d | -4d | 3d | 29d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years